MARKET

ACOR

ACOR

Acorda Thrpeutcs
NASDAQ
10.42
+0.10
+1.00%
Opening 12:41 12/04 EST
OPEN
10.10
PREV CLOSE
10.32
HIGH
10.49
LOW
10.10
VOLUME
1.73K
TURNOVER
0
52 WEEK HIGH
24.20
52 WEEK LOW
8.98
MARKET CAP
12.95M
P/E (TTM)
-0.8121
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ACOR last week (1127-1201)?
Weekly Report · 1d ago
Acorda Thrpeutcs: Current report
Press release · 4d ago
Weekly Report: what happened at ACOR last week (1120-1124)?
Weekly Report · 11/27 09:25
A Look Into Healthcare Sector Value Stocks
Value stocks are considered to be notable value stocks in the healthcare sector. Low p/e multiples are a good indicator that a company is undervalued. Nuwellis, exicure and acorda therapeutics are among the companies considered a notable value stock in the sector.
Benzinga · 11/20 14:44
Weekly Report: what happened at ACOR last week (1113-1117)?
Weekly Report · 11/20 09:25
Acorda Thrpeutcs: Quarterly report
Press release · 11/14 14:36
Acorda Thrpeutcs: Current report
Press release · 11/14 09:19
Acorda Therapeutics Q3 EPS $(7.16) Up From $(11.00) YoY, Sales $27.71M Down From $33.51M YoY
Acorda therapeutics reported quarterly losses of $7.16 per share. The company reported $27.71 million in sales this quarter. This is a decrease of 17.30 percent over sales of the same period last year. The company reported a 34.91 percent increase in losses.
Benzinga · 11/13 21:45
More
About ACOR
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The Company uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company’s commercial products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). Inbrija is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson’s disease treated with carbidopa/levodopa regimen. Inbrija utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

Webull offers Acorda Therapeutics Inc stock information, including NASDAQ: ACOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACOR stock methods without spending real money on the virtual paper trading platform.